Meropenem Trihydrate containing Meropenem trihydrate (equivalent to Meropenem) as active ingredient, is available as 1 g of sterile powder for IV injection in vial pack.
Meropenem Trihydrate is indicated for treatment of the following infections, in adults and children, caused by single or multiple bacteria sensitive to Meropenem :
Pneumonias including nosocomial pneumonia; peritonitis; meningitis; septicaemia.
Empiric treatment, for presumed infections in adult patients with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents.
Meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections.
The dosage and duration of therapy shall be established depending on type and severity of infection and condition of the patients.
Recommended daily dosage : 1 g IV every 8 hours in the treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia. In meningitis the recommended dosage is 2 g every 8 hours. As with antibiotics, particular caution is recommended in using Meropenem as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa lower respiratory tract infection. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infection.
Adults with hepatic insufficiency : No dosage adjustment is necessary in patients with hepatic insufficiency.
Elderly : No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values > 50 ml/min.
For children over 3 months and up to 12 years of age : Recommended dose is 10-20 mg/kg every 8 hours depending on type and severity of infection, susceptibility of the pathogen and patient condition.
In children > 50 kg weight, adults dosage should be used.
Meningitis : Recommended dose : 40 mg/kg every 8 hours.
There is no experience in children with renal impairment.